Syncona Limited Market Cap ($8.98 Million)
Market Cap & Net Worth: Syncona Limited (SYNC)
Syncona Limited market cap. Syncona Limited (LSE:SYNC) has a market capitalization of $8.98 Million (GBX73.83 Billion) as of November 5, 2026. Listed on the LSE stock exchange, this UK-based company holds position #27212 globally and #371 in its home market, demonstrating a -4.26% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Syncona Limited's stock price GBX121.40 by its total outstanding shares 608193024 (608.19 Million). Also see SYNC cash flow conversion for how efficiently the company converts equity into cash flow.
Syncona Limited Market Cap History (2015–2026)
Syncona Limited market cap history from 2015 to 2026. Data shows change from $9.43 Million to $8.98 Million (-0.58% CAGR). Check current stock price of Syncona Limited for real-time trading data and today's change.
Index Memberships
Syncona Limited is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
FTSE All-Share
FTAS
|
$67.79 Billion | 0.01% | #273 of 573 |
|
FTSE 350
FTLC
|
$67.73 Billion | 0.01% | #263 of 350 |
|
FTSE 250
FTMC
|
$9.58 Billion | 0.09% | #176 of 250 |
Weight: Syncona Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Syncona Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Syncona Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Syncona Limited to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
-0.10x
Syncona Limited's market cap is -0.10 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $9.97 Million | $4.75 Million | -$1.00 Million | 2.10x | N/A |
| 2017 | $14.91 Million | $83.16 Million | $77.29 Million | 0.18x | 0.19x |
| 2018 | $19.79 Million | $196.44 Million | $172.83 Million | 0.10x | 0.11x |
| 2019 | $16.21 Million | $439.12 Million | $411.26 Million | 0.04x | 0.04x |
| 2020 | $19.31 Million | $-167.31 Million | -$195.56 Million | -0.12x | N/A |
| 2021 | $15.69 Million | $78.54 Million | $53.16 Million | 0.20x | 0.30x |
| 2022 | $13.39 Million | $18.69 Million | $8.84 Million | 0.72x | 1.52x |
| 2023 | $9.13 Million | $-39.79 Million | -$56.02 Million | -0.23x | N/A |
| 2024 | $7.81 Million | $30.75 Million | $3.79 Million | 0.25x | 2.06x |
| 2025 | $7.03 Million | $-68.31 Million | -$143.16 Million | -0.10x | N/A |
Competitor Companies of SYNC by Market Capitalization
Companies near Syncona Limited in the global market cap rankings as of November 5, 2026. Also see how large is Syncona Limited's balance sheet for a full breakdown of the balance sheet.
Key companies related to Syncona Limited by market ranking:
- BlackRock Inc (NYSE:BLK): Ranked #134 globally with a market cap of $167.86 Billion USD.
- Brookfield Corporation (TO:BN): Ranked #263 globally with a market cap of $97.71 Billion USD ( CA$135.07 Billion CAD).
- Blackstone Group Inc (NYSE:BX): Ranked #274 globally with a market cap of $94.50 Billion USD.
- KKR & Co. Inc. (NYSE:KKR): Ranked #286 globally with a market cap of $90.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #134 | BlackRock Inc | NYSE:BLK | $167.86 Billion | $1224.37 |
| #263 | Brookfield Corporation | TO:BN | $97.71 Billion | CA$60.18 |
| #274 | Blackstone Group Inc | NYSE:BX | $94.50 Billion | $125.57 |
| #286 | KKR & Co. Inc. | NYSE:KKR | $90.97 Billion | $101.34 |
Market Capitalization of Syncona Limited (2015–2026)
Market capitalization of Syncona Limited from 2015 to today. Between 2015 and today, Syncona Limited's market cap moved from $9.43 Million to $ 8.98 Million, with a yearly change of -0.58%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | GBX8.98 Million | +27.79% |
| 2025 | GBX7.03 Million | -10.04% |
| 2024 | GBX7.81 Million | -14.42% |
| 2023 | GBX9.13 Million | -31.82% |
| 2022 | GBX13.39 Million | -14.62% |
| 2021 | GBX15.69 Million | -18.77% |
| 2020 | GBX19.31 Million | +19.18% |
| 2019 | GBX16.21 Million | -18.12% |
| 2018 | GBX19.79 Million | +32.77% |
| 2017 | GBX14.91 Million | +49.56% |
| 2016 | GBX9.97 Million | +5.70% |
| 2015 | GBX9.43 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Syncona Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.98 Million USD |
| MoneyControl | $8.98 Million USD |
| MarketWatch | $8.98 Million USD |
| marketcap.company | $8.98 Million USD |
| Reuters | $8.98 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Syncona Limited
Syncona Limited is a fund specializes in investments in hedge, equity and long-term alternative investment funds across multiple asset classes. It manages private equity, debt, fixed income and alternative investments. The fund prefers to invest in healthcare and life sciences sector with focus on Cell therapy, gene therapy, biologics and small molecules. The fund invests in the public equity and… Read more